Extracellular histones activate autophagy and apoptosis via mTOR signaling in human endothelial cells
Por:
J. IBANEZ-CABELLOS, C. AGUADO, D. PEREZ-CREMADES, J. GARCIA-GIMENEZ, C. BUENO-BETI, E. GARCIA-LOPEZ, C. ROMA-MATEO, S. NOVELLA, C. HERMENEGILDO and F. PALLARDO
Publicada:
1 oct 2018
Resumen:
Circulating histones have been proposed as targets for therapy in sepsis and hyperinflammatory symptoms. However, the proposed strategies have failed in clinical trials. Although different mechanisms for histone-related cytotoxicity are being explored, those mediated by circulating histones are not fully understood. Extracellular histones induce endothelial cell death, thereby contributing to the pathogenesis of complex diseases such as sepsis and septic shock. Therefore, the comprehension of cellular responses triggered by histones is capital to design effective therapeutic strategies. Here we report how extracellular histones induce autophagy and apoptosis in a dose-dependent manner in cultured human endothelial cells. In addition, we describe how histones regulate these pathways via Sestrin2/AMPK/ULK1-mTOR and AKT/mTOR. Furthermore, we evaluate the effect of Toll-like receptors in mediating autophagy and apoptosis demonstrating how TLR inhibitors do not prevent apoptosis and/or autophagy induced by histones. Our results confirm that histones and autophagic pathways can be considered as novel targets to design therapeutic strategies in endothelial damage.
Filiaciones:
:
Inst Hlth Carlos III, Ctr Biomed Network Res Rare Dis CIBERER, Valencia, Spain
INCLIVA CIPF Joint Unit Rare Dis, Valencia, Spain
Univ Valencia, Fac Med & Dent, Dept Physiol, Valencia, Spain
INCLIVA Biomed Res Inst, Valencia, Spain
:
Inst Hlth Carlos III, Ctr Biomed Network Res Rare Dis CIBERER, Valencia, Spain
INCLIVA CIPF Joint Unit Rare Dis, Valencia, Spain
CIPF, Valencia, Spain
D. PEREZ-CREMADES:
Univ Valencia, Fac Med & Dent, Dept Physiol, Valencia, Spain
INCLIVA Biomed Res Inst, Valencia, Spain
:
Inst Hlth Carlos III, Ctr Biomed Network Res Rare Dis CIBERER, Valencia, Spain
INCLIVA CIPF Joint Unit Rare Dis, Valencia, Spain
Univ Valencia, Fac Med & Dent, Dept Physiol, Valencia, Spain
INCLIVA Biomed Res Inst, Valencia, Spain
C. BUENO-BETI:
Univ Valencia, Fac Med & Dent, Dept Physiol, Valencia, Spain
INCLIVA Biomed Res Inst, Valencia, Spain
E. GARCIA-LOPEZ:
Univ Valencia, Fac Med & Dent, Dept Physiol, Valencia, Spain
INCLIVA Biomed Res Inst, Valencia, Spain
:
Inst Hlth Carlos III, Ctr Biomed Network Res Rare Dis CIBERER, Valencia, Spain
INCLIVA CIPF Joint Unit Rare Dis, Valencia, Spain
Univ Valencia, Fac Med & Dent, Dept Physiol, Valencia, Spain
INCLIVA Biomed Res Inst, Valencia, Spain
CIBERer UV INCLIVA, Epigenet Res Platform, Valencia, Spain
S. NOVELLA:
Univ Valencia, Fac Med & Dent, Dept Physiol, Valencia, Spain
INCLIVA Biomed Res Inst, Valencia, Spain
C. HERMENEGILDO:
Univ Valencia, Fac Med & Dent, Dept Physiol, Valencia, Spain
INCLIVA Biomed Res Inst, Valencia, Spain
:
Inst Hlth Carlos III, Ctr Biomed Network Res Rare Dis CIBERER, Valencia, Spain
INCLIVA CIPF Joint Unit Rare Dis, Valencia, Spain
Univ Valencia, Fac Med & Dent, Dept Physiol, Valencia, Spain
INCLIVA Biomed Res Inst, Valencia, Spain
|